KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2016 - 2025)

Regeneron Pharmaceuticals has reported Long-Term Deferred Tax over the past 15 years, most recently at $4.1 billion for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $4.1 billion for Q4 2025, up 23.03% from a year ago — trailing twelve months through Dec 2025 was $4.1 billion (up 23.03% YoY), and the annual figure for FY2025 was $4.1 billion, up 23.03%.
  • Long-Term Deferred Tax for Q4 2025 was $4.1 billion at Regeneron Pharmaceuticals, up from $3.8 billion in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for REGN hit a ceiling of $4.1 billion in Q4 2025 and a floor of $723.2 million in Q3 2021.
  • Median Long-Term Deferred Tax over the past 5 years was $2.2 billion (2023), compared with a mean of $2.2 billion.
  • Biggest five-year swings in Long-Term Deferred Tax: fell 10.07% in 2021 and later soared 100.79% in 2022.
  • Regeneron Pharmaceuticals' Long-Term Deferred Tax stood at $876.9 million in 2021, then soared by 96.57% to $1.7 billion in 2022, then soared by 49.41% to $2.6 billion in 2023, then increased by 28.68% to $3.3 billion in 2024, then grew by 23.03% to $4.1 billion in 2025.
  • The last three reported values for Long-Term Deferred Tax were $4.1 billion (Q4 2025), $3.8 billion (Q3 2025), and $3.6 billion (Q2 2025) per Business Quant data.